PALO ALTO, Calif., Dec. 6, 2019 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced the closing of
its previously announced underwritten public offering of 6,900,000
shares of its common stock, which includes 900,000 shares sold
pursuant to the underwriters' exercise in full of their option to
purchase additional shares, at a price to the public of
$46.00 per share. The aggregate gross
proceeds from the offering were approximately $317.4 million, before deducting the underwriting
discounts and commissions and estimated offering expenses payable
by Kodiak Sciences.
J.P. Morgan, Goldman Sachs & Co. LLC and Jefferies acted as
joint book-running managers for the offering. SunTrust Robinson
Humphrey acted as lead manager. Chardan acted as co-manager.
The shares described above were offered by Kodiak Sciences
pursuant to a shelf registration statement on Form S-3, including a
base prospectus, that was previously filed by Kodiak Sciences with
the Securities and Exchange Commission (the "SEC") and was declared
effective on November 14, 2019. A
final prospectus supplement and accompanying prospectus relating to
the offering have been filed with the SEC, and are available on the
SEC's website located at http://www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
the offering may be obtained from: J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone
at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com;
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, New York
10282, by telephone at 866-471-2526, by facsimile at (212) 902-9316
or by email at prospectus-ny@ny.email.gs.com; or Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 2nd Floor, New York, NY
10022, by telephone at (877) 821-7388, or by email at
Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Kodiak Sciences Inc.
Kodiak™ is a clinical stage biopharmaceutical company specializing
in novel therapeutics to treat chronic, high-prevalence retinal
diseases. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration and diabetic eye diseases.
"Kodiak," "ABC Platform" and the Kodiak logo are registered
trademarks or trademarks of Kodiak Sciences Inc. in various
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-closing-of-317-4-million-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-300970654.html
SOURCE Kodiak Sciences Inc.